Dendreon's Provenge Therapeutic Cancer Vaccine Has A May 15 PDUFA Date
This article was originally published in The Pink Sheet Daily
Executive Summary
The prostate cancer immunotherapeutic is the first therapeutic cancer vaccine accepted for review by FDA.
You may also be interested in...
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Prostate cancer immunotherapy reduces risk of death by 20 percent compared with placebo, but falls shy of target.
Provenge Fails To Meet Interim Study Endpoint, But Dendreon Will Press On
Dendreon will have to wait until mid-2009 at the earliest for final study results of its prostate cancer vaccine Provenge, after it failed to meet the primary endpoint in an interim look at the data